Topical Drugs Contract Development And Manufacturing Organization (CDMO) Market Report 2026

Topical Drugs Contract Development And Manufacturing Organization (CDMO) Market Overview

• Topical Drugs Contract Development And Manufacturing Organization (CDMO) market size has reached to $61.16 billion in 2025 • Expected to grow to $121.22 billion in 2030 at a compound annual growth rate (CAGR) of 14.3% • Growth Driver: Rising Skin Disease Prevalence Fuels Growth In The Topical Drugs CDMO Market • Market Trend: Focus On State-of-the-Art Manufacturing Facilities In The Topical Drugs CDMO Market • Asia-Pacific was the largest region in 2025.

What Is Covered Under Topical Drugs Contract Development And Manufacturing Organization (CDMO) Market?

A topical drugs contract development and manufacturing organization (CDMO) is a specialized company that provides comprehensive services for the development, formulation, and production of topical pharmaceuticals. These services include research and development, clinical trial material production, and commercial manufacturing. CDMOs help pharmaceutical companies bring topical drug products to market efficiently and compliantly. The main product types of topical drug contract development and manufacturing organization (CDMO) are semi-solid formulations, liquid formulations, solid formulations, and transdermal products. Semi-solid formulations include creams, ointments, gels, and pastes designed for topical application. Various service types include contract development, contract manufacturing for a variety of therapeutic areas such as dermatology, pain management, wound care, and ophthalmology, and others. These are used by different end-uses, which include pharmaceutical companies, biopharmaceutical companies, and others.

What Is The Topical Drugs Contract Development And Manufacturing Organization (CDMO) Market Growth Forecast?

The topical drugs contract development and manufacturing organization (cdmo) market size is expected to see rapid growth in the next few years. It will grow to $121.22 billion in 2030 at a compound annual growth rate (CAGR) of 14.3%. The growth in the forecast period can be attributed to increasing development of advanced topical therapies, rising demand for transdermal patches, expansion of small and mid-sized pharma pipelines, growing need for scalable manufacturing, increased focus on speed to market. Major trends in the forecast period include rising outsourcing of topical drug manufacturing, growing demand for complex topical formulations, expansion of transdermal drug delivery platforms, increasing focus on regulatory-compliant manufacturing, higher demand for end-to-end CDMO services.

Global Topical Drugs Contract Development And Manufacturing Organization (CDMO) Market Segmentation

1) By Product Type: Semi-Solid Formulations, Liquid Formulations Drugs, Solid Formulations, Transdermal Products 2) By Service Type: Contract Development, Contract Manufacturing 3) By Therapeutic Area: Dermatology, Pain Management, Wound Care, Ophthalmology, Other Therapeutic Areas 4) By End-Use: Pharmaceutical Companies, Biopharmaceutical Companies, Other End-Uses Subsegments: 1) By Semi-Solid Formulations: Creams, Ointments, Gels, Pastes 2) By Liquid Formulations Drugs: Solutions, Suspensions, Emulsions, Lotions 3) By Solid Formulations: Powders 4) By Transdermal Products: Patches

What Is The Driver Of The Topical Drugs Contract Development And Manufacturing Organization (CDMO) Market?

The increasing prevalence of skin diseases is expected to propel the growth of the topical drugs contract development and manufacturing organization (CDMO) market going forward. Skin diseases refer to medical conditions that affect the skin, causing symptoms such as inflammation, itching, and lesions. The increasing prevalence of skin diseases can be attributed to factors such as environmental pollution, UV radiation exposure, genetic predisposition, lifestyle changes, and microbial infections. Topical drugs contract development and manufacturing organization (CDMO) helps reduce skin disease prevalence by developing and manufacturing targeted therapies that improve the management and treatment of dermatological conditions. For instance, in 2023, according to Cancer Australia, an Australia-based government agency, approximately 8,257 new cases of melanoma of the skin were diagnosed, accounting for 2.6% of all deaths from cancer. Therefore, the increasing prevalence of skin diseases is driving the growth of the topical drugs contract development and manufacturing organization (CDMO) industry.

Key Players In The Global Topical Drugs Contract Development And Manufacturing Organization (CDMO) Market

Major companies operating in the topical drugs contract development and manufacturing organization (cdmo) market are Catalent Inc., Lonza Group AG, Recipharm AB, Piramal Pharma Solutions, Cambrex Corporation, PCI Pharma Services, Famar S.A., Contract Pharmaceuticals Limited, UPM Pharmaceuticals Inc., MedPharm Ltd, Tergus Pharma LLC, NextPharma Technologies Holding Limited, Bora Pharmaceuticals Co. Ltd., LTS Lohmann Therapie-Systeme AG, CoreRx Inc., Halo Pharmaceutical Inc., Tapemark Company, Groupe PARIMA Inc., Dow Development Laboratories LLC, Tedor Pharma Inc.

Global Topical Drugs Contract Development And Manufacturing Organization (CDMO) Market Trends and Insights

Major companies operating in the topical drugs contract development and manufacturing organization (CDMO) market are focused on developing state-of-the-art manufacturing facilities to sustain their position in the market. A state-of-the-art manufacturing facility is a specialized production site equipped with the latest technology and advanced processes tailored for the development and manufacturing of topical pharmaceutical products. For instance, in November 2023, SOHM Inc., a US-based pharmaceutical company, launched a CDMO GMP manufacturing facility. The new Carlsbad facility will offer ample space for manufacturing topical products and SOHM's operations, with 2,500 square feet dedicated to storing finished products. Initially, it will have a daily capacity of 500 gallons (1,892 liters) for manufacturing topicals. By the end of Q1 2024 or the start of Q2 2024, it is expected to expand its capacity to include soft-gel suppositories.

What Are Latest Mergers And Acquisitions In The Topical Drugs Contract Development And Manufacturing Organization (CDMO) Market?

In April 2024, CoreRx Inc., a US-based pharmaceutical company, acquired Societal CDMO Inc. for $130 million. The acquisition is set to enhance CoreRx into a stronger CDMO, expanding its services from early-stage development to commercial manufacturing. It will streamline operations, increase market share, and provide long-term benefits such as improved economies of scale, better R&D, and a stronger competitive position. Societal CDMO Inc. is a US-based contract development and manufacturing organization that specializes in developing and manufacturing novel drug delivery formulations.

Regional Insights

Asia-Pacific was the largest region in the topical drugs contract development and manufacturing organization (CDMO) market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Topical Drugs Contract Development And Manufacturing Organization (CDMO) Market?

The topical drugs contract development and manufacturing organization (CDMO) market consists of revenues earned by entities by providing services such as commercial manufacturing, research and development (R&D), regulatory support, and product lifecycle management. The market value includes the value of related goods sold by the service provider or included within the service offering. The topical drugs contract development and manufacturing organization (CDMO) market also includes sales of creams, ointments, gels, and lotions. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Topical Drugs Contract Development And Manufacturing Organization (CDMO) Market Report 2026?

The topical drugs contract development and manufacturing organization (cdmo) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the topical drugs contract development and manufacturing organization (cdmo) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.